Dateline City:
KENILWORTH, N.J. & MISGAV, Israel
KENILWORTH, N.J. & MISGAV, Israel--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
cCAM Biotherapeutics announced today that the companies have signed a
definitive agreement under which Merck will acquire cCAM
Biotherapeutics, a privately held biopharmaceutical company focused on
the discovery and development of novel cancer immunotherapies.
Language:
English
Contact:
Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orcCAM Investor/Media Relations:Tsipi Haitovsky, +972-525-989892
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more